Onesource Specialty Pharma (OSPL) announced that India Ratings and Research has upgraded the company's long-term rating to 'IND A' from 'IND A-' with a 'positive' outlook. According to reports from Business Standard, the rating on the short-term facilities has been reaffirmed at IND A1. This upgrade reflects the strengthening of OSPL's business profile following the successful commercialisation of its drug device combination (DOC) platform and increasing contribution from commercial glucagon-like peptide-1 (GLP-1) supplies. The upgrade also benefits from OSPL's established presence in regulated markets and integrated manufacturing capabilities across its diversified CDMO platform. As per India Ratings & Research (Ind-Ra), the positive rating action is attributed to OSPL's strengthening business profile, with the upgrade encompassing the company's bank loan facilities.
India Ratings believes the company has transitioned from a predominantly development-led revenue model to an increasingly commercial supply-led model, supported by multiple customer launches, long-term supply agreements, and capacity expansion. As reported by Business Standard, the demonstrated conversion of development projects into commercial supplies and the ramp-up of commercial revenue have improved revenue visibility, strengthened customer stickiness, and reduced execution risk. The ratings continue to benefit from OSPL's diversified contract development and manufacturing organisation (CDMO) platform across DDCs, biologics, sterile injectables and softgels, supported by an established presence in regulated markets and integrated manufacturing capabilities. According to India Ratings & Research (Ind-Ra), the company's transition from a development-led to a supply-led revenue model is supported by new customer launches, long-term supply agreements, and capacity expansions.
The agency has observed a significant improvement in the company's scale of EBITDA during 4Q FY26 - 1Q FY27, led by the genericisation of GLP-1 portfolio in various markets. According to Business Standard, India Ratings expects increasing utilisation of expanded capacities, growing CSA revenues, and improving operating leverage to support stronger profitability, cash flow generation and gradual deleveraging over the medium term. The Positive Outlook indicates Ind-Ra's expectation of continued improvement in OSPL's business profile and credit metrics over the medium term. This is anticipated due to the ramp-up of commercial GLP-1 opportunities, increasing commercial supply agreement revenue, and capacity utilization. The agency anticipates leverage to decline below 2x by FY28.
Onesource Specialty Pharma is a fully integrated, multi-modality specialty pharmaceutical CDMO company, focused on developing and manufacturing drug-device combinations (DDCs), biologics, sterile injectables and oral technologies like soft gelatin capsules for its customers out of five globally compliant facilities located in Bengaluru. As reported by Business Standard, the scrip shed 0.32% to currently trade at ₹1,546.95 on the BSE following the announcement. The upgrade reflects the company's strengthened business profile and commercial success, with the details of the instruments and their ratings, including specific bank facilities, provided in the accompanying documentation.
